BG108019A - Parenteral formulation containing epothilone analogs - Google Patents

Parenteral formulation containing epothilone analogs

Info

Publication number: BG108019A
Authority: BG; Bulgaria
Prior art keywords: vial; diluent; analog; epothilone; mixture
Prior art date: 2001-01-25

Application number

BG108019A

Other languages

Bulgarian (bg)

English (en)

Inventor

Rebanta Bandyopadhyay

Timothy M. Malloy

Andrea Panaggio

Krishnaswamy S. Raghavan

Sailesh A. Varia

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-25

Filing date

2003-07-22

Publication date

2004-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23005123&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG108019(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-07-22 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2004-09-30 Publication of BG108019A publication Critical patent/BG108019A/xx

Links

229930013356 epothilone Natural products 0.000 title abstract 4
150000003883 epothilone derivatives Chemical class 0.000 title abstract 4
239000000203 mixture Substances 0.000 title abstract 3
238000009472 formulation Methods 0.000 title 1
239000003085 diluting agent Substances 0.000 abstract 3
239000000243 solution Substances 0.000 abstract 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
239000008156 Ringer's lactate solution Substances 0.000 abstract 1
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 abstract 1
BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical group O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 abstract 1
238000010253 intravenous injection Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000002736 nonionic surfactant Substances 0.000 abstract 1
238000007911 parenteral administration Methods 0.000 abstract 1
239000008389 polyethoxylated castor oil Substances 0.000 abstract 1
239000002904 solvent Substances 0.000 abstract 1
239000004094 surface-active agent Substances 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

BG108019A 2001-01-25 2003-07-22 Parenteral formulation containing epothilone analogs BG108019A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US26422801P	2001-01-25	2001-01-25
PCT/US2002/001102 WO2002062338A1 (en)	2001-01-25	2002-01-16	Parenteral formulation containing epothilone analogs

Publications (1)

Publication Number	Publication Date
BG108019A true BG108019A (en)	2004-09-30

Family

ID=23005123

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG108019A BG108019A (en)	2001-01-25	2003-07-22	Parenteral formulation containing epothilone analogs

Country Status (24)

Country	Link
US (5)	US7022330B2 (is)
EP (1)	EP1353667A1 (is)
JP (1)	JP2004521122A (is)
KR (1)	KR20030071853A (is)
CN (2)	CN1489466A (is)
AR (2)	AR032408A1 (is)
BG (1)	BG108019A (is)
BR (1)	BR0206511A (is)
CA (2)	CA2434566A1 (is)
CZ (1)	CZ20032022A3 (is)
EE (1)	EE200300323A (is)
HU (1)	HUP0302567A2 (is)
IL (1)	IL156580A0 (is)
IS (1)	IS6890A (is)
MX (1)	MXPA03006485A (is)
NO (1)	NO20033342L (is)
PE (1)	PE20020733A1 (is)
PL (1)	PL367260A1 (is)
RU (1)	RU2003126171A (is)
SI (1)	SI1353668T1 (is)
SK (1)	SK8552003A3 (is)
UY (1)	UY27134A1 (is)
WO (1)	WO2002062338A1 (is)
ZA (3)	ZA200305123B (is)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6867305B2 (en)	1996-12-03	2005-03-15	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6204388B1 (en) *	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
WO1999001124A1 (en)	1996-12-03	1999-01-14	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) *	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
UA75365C2 (en) *	2000-08-16	2006-04-17	Bristol Myers Squibb Co	Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
IL156580A0 (en) *	2001-01-25	2004-01-04	Bristol Myers Squibb Co	A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
BR0207487A (pt)	2001-02-20	2004-08-10	Brystol Myers Squibb Company	Método de tratamento de tumores em mamìferos e uso de compostos de epotilona
WO2002072085A1 (en) *	2001-03-14	2002-09-19	Bristol-Myers Squibb Company	Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
TW200400191A (en) *	2002-05-15	2004-01-01	Bristol Myers Squibb Co	Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US6921769B2 (en)	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en)	2002-08-23	2010-01-19	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
DE60330407D1 (de)	2002-08-23	2010-01-14	Sloan Kettering Inst Cancer	Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
US20050171167A1 (en) *	2003-11-04	2005-08-04	Haby Thomas A.	Process and formulation containing epothilones and analogs thereof
US20050136105A1 (en) *	2003-12-22	2005-06-23	Allen Marni L.	Consumer customized dosage forms
ES2809302T3 (es) *	2004-01-22	2021-03-03	Univ Miami	Formulaciones de coenzima Q10 para tratar tumores sólidos mediante administración intravenosa
RS50510B (sr)	2004-10-29	2010-03-02	Pharma Mar S.A., Sociedad Unipersonal	Formulacije koje sadrže ekteinascidin i disaharid
AR052142A1 (es) *	2004-11-18	2007-03-07	Bristol Myers Squibb Co	Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma
EP1824458A1 (en) *	2004-11-18	2007-08-29	Bristol-Myers Squibb Company	Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
EP1674098A1 (en) *	2004-12-23	2006-06-28	Schering Aktiengesellschaft	Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
EP2634252B1 (en)	2005-02-11	2018-12-19	University of Southern California	Method of expressing proteins with disulfide bridges
GB0522082D0 (en)	2005-10-31	2005-12-07	Pharma Mar Sa	Formulations
US8158152B2 (en) *	2005-11-18	2012-04-17	Scidose Llc	Lyophilization process and products obtained thereby
US8008256B2 (en) *	2006-05-01	2011-08-30	University Of Southern California	Combination therapy for treatment of cancer
EP2023923A2 (en) *	2006-05-25	2009-02-18	Bristol-Myers Squibb Company	Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals
CN101732310B (zh) *	2006-07-12	2011-07-20	湖南迪诺制药有限公司	埃博霉素b的用途
WO2010056901A2 (en)	2008-11-13	2010-05-20	University Of Southern California	Method of expressing proteins with disulfide bridges with enhanced yields and activity
WO2010056847A2 (en) *	2008-11-13	2010-05-20	Taigen Biotechnology Co., Ltd.	Lyophilization formulation
AU2010247800A1 (en)	2009-05-11	2011-12-15	Berg Llc	Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
AU2011255647A1 (en)	2010-05-18	2012-11-15	Cerulean Pharma Inc.	Compositions and methods for treatment of autoimmune and other diseases
US8618146B2 (en)	2011-01-03	2013-12-31	Dr. Reddy's Laboratories Limited	Epothilone compound formulations
CA2832324C (en)	2011-04-04	2022-03-15	Berg Llc	Methods of treating central nervous system tumors
JP2014516075A (ja)	2011-06-06	2014-07-07	シェブロンフィリップスケミカルカンパニーエルピー	癌治療のためのメタロセン化合物の使用
SG10201903112WA (en)	2013-04-08	2019-05-30	Berg Llc	Treatment of cancer using coenzyme q10 combination therapies
KR102370843B1 (ko)	2013-09-04	2022-03-04	버그 엘엘씨	코엔자임 q10의 연속주입에 의한 암치료 방법
WO2017087576A1 (en)	2015-11-16	2017-05-26	Berg Llc	Methods of treatment of temozolomide-resistant glioma using coenzyme q10
CN107041886A (zh) *	2016-02-06	2017-08-15	北京华昊中天生物技术有限公司	脱环氧埃坡霉素衍生物制剂、制备及其治疗肿瘤的应用
HRP20231233T1 (hr)	2017-04-27	2024-01-19	Pharma Mar, S.A.	Antitumorski spojevi
BR112022013685A2 (pt)	2020-01-10	2022-09-06	R Pharm Us Operating Llc	Composições de ixabepilona
CN114727995B (zh)	2020-09-02	2024-06-11	北京华昊中天生物医药股份有限公司	优替德隆的固体口服制剂

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4950432A (en) *	1987-10-16	1990-08-21	Board Of Regents, The University Of Texas System	Polyene microlide pre-liposomal powders
DE4138042C2 (de)	1991-11-19	1993-10-14	Biotechnolog Forschung Gmbh	Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DK1186606T4 (da)	1995-11-17	2011-12-05	Biotechnolog Forschung Gmbh	Epothilonderivater, deres fremstilling og anvendelse
DE19542986A1 (de)	1995-11-17	1997-05-22	Biotechnolog Forschung Gmbh	Epothilon-Derivate und deren Verwendung
DE19639456A1 (de)	1996-09-25	1998-03-26	Biotechnolog Forschung Gmbh	Epothilon-Derivate, Herstellung und Mittel
JP3486283B2 (ja) *	1996-01-31	2004-01-13	三菱重工業株式会社	重質油の脱水方法
DE69735057T2 (de)	1996-03-12	2006-08-31	PG-TXL Co., L.P., Houston	Wasserlösliche paclitaxel-prodrogen
US6441025B2 (en)	1996-03-12	2002-08-27	Pg-Txl Company, L.P.	Water soluble paclitaxel derivatives
DE19636343C1 (de)	1996-08-30	1997-10-23	Schering Ag	Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DE19645361A1 (de)	1996-08-30	1998-04-30	Ciba Geigy Ag	Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
EP0923583A1 (de)	1996-08-30	1999-06-23	Novartis AG	Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
DE19645362A1 (de)	1996-10-28	1998-04-30	Ciba Geigy Ag	Verfahren zur Herstellung von Epothilon A und B und Derivaten
DK1367057T3 (da)	1996-11-18	2009-01-19	Biotechnolog Forschung Gmbh	Epothiloner E og F
US6515016B2 (en)	1996-12-02	2003-02-04	Angiotech Pharmaceuticals, Inc.	Composition and methods of paclitaxel for treating psoriasis
US6204388B1 (en)	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
WO1999001124A1 (en) *	1996-12-03	1999-01-14	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en)	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
US6380394B1 (en)	1996-12-13	2002-04-30	The Scripps Research Institute	Epothilone analogs
DE19701758A1 (de)	1997-01-20	1998-07-23	Wessjohann Ludgar A Dr	Epothilone-Synthesebausteine
PT975638E (pt)	1997-02-25	2002-12-31	Biotechnolog Forschung Mbh Gbf	Epothilons modificados nas cadeias laterais
DE19713970B4 (de)	1997-04-04	2006-08-31	R&D-Biopharmaceuticals Gmbh	Epothilone-Synthesebausteine II - Prenylderivate
WO1998047891A1 (de)	1997-04-18	1998-10-29	Studiengesellschaft Kohle Mbh	Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19821954A1 (de)	1997-05-15	1998-11-19	Biotechnolog Forschung Gmbh	Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de)	1997-05-15	1998-11-19	Hoechst Ag	Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de)	1997-06-17	1998-12-24	Schering Ag	Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) *	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
US6384230B1 (en)	1997-07-16	2002-05-07	Schering Aktiengesellschaft	Thiazole derivatives, method for their production and use
ES2290993T3 (es)	1997-08-09	2008-02-16	Bayer Schering Pharma Aktiengesellschaft	Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
ATE215820T1 (de) *	1997-10-08	2002-04-15	Sepracor Inc	Dosierungsform zur verabreichung von aerosolen
US6365749B1 (en)	1997-12-04	2002-04-02	Bristol-Myers Squibb Company	Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
AU1983099A (en)	1998-01-23	1999-08-09	Sanyo Electric Co., Ltd.	Reproducing method for magneto-optic recording medium, and magneto-optic disk device
SK287775B6 (sk)	1998-02-05	2011-09-05	Novartis Ag	Farmaceutická formulácia obsahujúca epothilon, infúzny roztok a použitie farmaceutickej formulácie
US6683100B2 (en) *	1999-01-19	2004-01-27	Novartis Ag	Organic compounds
US6194181B1 (en)	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr) *	1998-02-25	2003-02-21	Novartis Ag	Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
DE69927790T2 (de)	1998-02-25	2006-07-20	Sloan-Kettering Institute For Cancer Research	Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen
US6399638B1 (en)	1998-04-21	2002-06-04	Bristol-Myers Squibb Company	12,13-modified epothilone derivatives
WO2000000485A1 (de)	1998-06-30	2000-01-06	Schering Aktiengesellschaft	Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
NZ511722A (en)	1998-11-20	2004-05-28	Kosan Biosciences Inc	Recombinant methods and materials for producing epothilone and epothilone derivatives
CN1122668C (zh)	1998-12-22	2003-10-01	诺瓦提斯公司	环氧噻酮衍生物，其制备方法及其药物组合物
US6780620B1 (en)	1998-12-23	2004-08-24	Bristol-Myers Squibb Company	Microbial transformation method for the preparation of an epothilone
YU59001A (sh)	1999-02-18	2005-07-19	Schering Ag.	16-halogen-epotilon-derivati, postupak za njihovo dobijanje i njihova farmaceutska primena
BR0008379A (pt)	1999-02-22	2002-09-24	Biotechnolog Forschung Gmbh	Epotilonas modificadas em c-21
US6211412B1 (en)	1999-03-29	2001-04-03	The University Of Kansas	Synthesis of epothilones
AU772750C (en) *	1999-04-30	2005-02-24	Schering Aktiengesellschaft	6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
AR023792A1 (es)	1999-04-30	2002-09-04	Bayer Schering Pharma Ag	Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
US6364749B1 (en) *	1999-09-02	2002-04-02	Micron Technology, Inc.	CMP polishing pad with hydrophilic surfaces for enhanced wetting
US6518421B1 (en)	2000-03-20	2003-02-11	Bristol-Myers Squibb Company	Process for the preparation of epothilone analogs
AU2001266583A1 (en)	2000-05-26	2001-12-11	Kosan Biosciences, Inc.	Epothilone derivatives and methods for making and using the same
UA75365C2 (en) *	2000-08-16	2006-04-17	Bristol Myers Squibb Co	Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
US20030017169A1 (en) *	2000-12-29	2003-01-23	Sidney Pestka	Controlled release systems for polymers
NZ526871A (en) *	2001-01-25	2006-01-27	Bristol Myers Squibb Co	Pharmaceutical dosage forms of epothilones for oral administration
HU229349B1 (en) *	2001-01-25	2013-11-28	Bristol Myers Squibb Co	Methods for preparation of pharmaceutical composition containing epothilone analogs useful for treatment of cancer
IL156580A0 (en) *	2001-01-25	2004-01-04	Bristol Myers Squibb Co	A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
BR0207487A (pt)	2001-02-20	2004-08-10	Brystol Myers Squibb Company	Método de tratamento de tumores em mamìferos e uso de compostos de epotilona

2002
- 2002-01-16 IL IL15658002A patent/IL156580A0/xx unknown
- 2002-01-16 MX MXPA03006485A patent/MXPA03006485A/es unknown
- 2002-01-16 EP EP02709040A patent/EP1353667A1/en not_active Withdrawn
- 2002-01-16 SK SK855-2003A patent/SK8552003A3/sk unknown
- 2002-01-16 RU RU2003126171/15A patent/RU2003126171A/ru not_active Application Discontinuation
- 2002-01-16 KR KR10-2003-7009824A patent/KR20030071853A/ko not_active Withdrawn
- 2002-01-16 WO PCT/US2002/001102 patent/WO2002062338A1/en not_active Ceased
- 2002-01-16 JP JP2002562345A patent/JP2004521122A/ja active Pending
- 2002-01-16 CZ CZ20032022A patent/CZ20032022A3/cs unknown
- 2002-01-16 PL PL02367260A patent/PL367260A1/xx not_active Application Discontinuation
- 2002-01-16 HU HU0302567A patent/HUP0302567A2/hu unknown
- 2002-01-16 BR BR0206511-8A patent/BR0206511A/pt not_active Application Discontinuation
- 2002-01-16 EE EEP200300323A patent/EE200300323A/xx unknown
- 2002-01-16 CA CA002434566A patent/CA2434566A1/en not_active Abandoned
- 2002-01-16 CN CNA028041798A patent/CN1489466A/zh active Pending
- 2002-01-17 US US10/051,727 patent/US7022330B2/en not_active Expired - Lifetime
- 2002-01-22 CN CN2007101422373A patent/CN101112373B/zh not_active Expired - Fee Related
- 2002-01-22 CA CA2681962A patent/CA2681962C/en not_active Expired - Lifetime
- 2002-01-22 SI SI200230687T patent/SI1353668T1/sl unknown
- 2002-01-25 UY UY27134A patent/UY27134A1/es not_active Application Discontinuation
- 2002-01-25 PE PE2002000060A patent/PE20020733A1/es not_active Application Discontinuation
- 2002-01-25 AR ARP020100286A patent/AR032408A1/es unknown
2003
- 2003-07-01 ZA ZA200305123A patent/ZA200305123B/en unknown
- 2003-07-01 ZA ZA200305126A patent/ZA200305126B/xx unknown
- 2003-07-17 ZA ZA200305536A patent/ZA200305536B/en unknown
- 2003-07-22 BG BG108019A patent/BG108019A/xx unknown
- 2003-07-24 IS IS6890A patent/IS6890A/is unknown
- 2003-07-24 NO NO20033342A patent/NO20033342L/no not_active Application Discontinuation
2005
- 2005-09-14 US US11/226,017 patent/US20060013836A1/en not_active Abandoned
2008
- 2008-11-04 US US12/264,375 patent/US8632788B2/en not_active Expired - Fee Related
2013
- 2013-12-19 US US14/134,172 patent/US20140107169A1/en not_active Abandoned
2014
- 2014-10-17 AR ARP140103915A patent/AR098109A2/es unknown
2015
- 2015-04-14 US US14/686,005 patent/US20150218179A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20140107169A1 (en)	2014-04-17
IL156580A0 (en)	2004-01-04
AR032408A1 (es)	2003-11-05
CA2681962C (en)	2012-06-12
CN1489466A (zh)	2004-04-14
WO2002062338A1 (en)	2002-08-15
US20090069393A1 (en)	2009-03-12
UY27134A1 (es)	2002-08-30
HUP0302567A2 (hu)	2003-12-29
PE20020733A1 (es)	2002-08-11
CA2681962A1 (en)	2002-08-01
RU2003126171A (ru)	2005-02-27
JP2004521122A (ja)	2004-07-15
BR0206511A (pt)	2003-10-21
SK8552003A3 (en)	2004-06-08
US7022330B2 (en)	2006-04-04
CZ20032022A3 (cs)	2004-04-14
AR098109A2 (es)	2016-05-04
US20150218179A1 (en)	2015-08-06
CA2434566A1 (en)	2002-08-15
SI1353668T1 (sl)	2008-08-31
ZA200305123B (en)	2004-10-01
NO20033342D0 (no)	2003-07-24
US20060013836A1 (en)	2006-01-19
US20020143038A1 (en)	2002-10-03
PL367260A1 (en)	2005-02-21
MXPA03006485A (es)	2003-09-22
ZA200305536B (en)	2004-09-06
US8632788B2 (en)	2014-01-21
KR20030071853A (ko)	2003-09-06
CN101112373A (zh)	2008-01-30
EE200300323A (et)	2003-10-15
CN101112373B (zh)	2012-06-20
ZA200305126B (en)	2004-10-01
EP1353667A1 (en)	2003-10-22
NO20033342L (no)	2003-09-22
IS6890A (is)	2003-07-24

Publication	Publication Date	Title
BG108019A (en)	2004-09-30	Parenteral formulation containing epothilone analogs
YU58203A (sh)	2006-08-17	Postupci primene epotilonskih analoga za lečenje kancera
KR950007858A (ko)	1995-04-15	정맥내 주사용 라파마이신 제형
CA2215327A1 (en)	1996-10-31	Formulations for lipophilic compounds
RU2002123180A (ru)	2004-03-20	Анестезирующие рецептуры
HUT67661A (en)	1995-04-28	New pyrazine derivatives, their preparation and pharmaceutical compositions containing them
AU8799201A (en)	2002-04-08	Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases
EA004708B1 (ru)	2004-06-24	Фармацевтическая композиция, включающая пеметрексед вместе с монотиоглицерином, l-цистеином или тиогликолевой кислотой
CA2466851C (en)	2012-09-11	Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
NO20033341L (no)	2003-09-04	Metoder for administrering av epothilone-analoger for behandling av kreft
US6020359A (en)	2000-02-01	Pharmaceutical composition
JPH0338519A (ja)	1991-02-19	ビタミンａ類含有点眼剤
ES2310550T3 (es)	2009-01-16	Preparacion liquida acuosa de pranoprofeno.
US6818662B2 (en)	2004-11-16	Pharmaceutical composition
US4089949A (en)	1978-05-16	Injectable therapeutic compositions
CA1282703C (en)	1991-04-09	Stable injectable antiemetic compositions
DE69211743D1 (de)	1996-08-01	Aureobasidin enthaltendes Arzneimittel
KR950016756A (ko)	1995-07-20	피로회복제 조성물
KR950016755A (ko)	1995-07-20	간염의 예방 및 치료용 의약조성물
TH17297A (th)	1995-12-27	ส่วนผสมทางเภสัชกรรม
TH40972B (th)	2000-10-31	สารประกอบอินทรีย์
BG106114A (en)	2003-05-30	Mastic and method for the preparation of a pharmaceutical form of paclitaxel